Print this page
-
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast -
A Phase II Study of U3-1402 in Patients with Metastatic Breast Cancer.
Protocol: 042103Principal Investigator:
- Deborah Toppmeyer M.D. (Rutgers University)
Applicable Disease Sites: Breast -
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*).
Protocol: 082101Principal Investigator:
- Malcolm Mattes (New Jersey Medical School)
Applicable Disease Sites: Prostate -
Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults.
Protocol: 022101Principal Investigator:
- Neil Palmisiano MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lymphoid Leukemia -
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer.
Protocol: 032103Principal Investigator:
- Dylan Roden (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System